»áÒéר°æ¹ã¸æ¡£Ð¡Ä¾³æÎÞ·¨È·±£»áÒéµÄÕæÊµÐÔ¡£Èç¹û·¢ÏÖÓÐÐé¼ÙÆÛÕ©»áÒ飬ÇëÁ¢¼´¾Ù±¨¸øÎÒÃÇ¡£ [¿¯µÇ»áÒé¡¢¾Ù±¨Ðé¼Ù»áÒé¹ã¸æ£¬¾ùÇëÁªÏµÎ¢ÐÅ£º18510626021 ]

±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1789  |  »Ø¸´: 55

dz×Ï΢À¶

ľ³æ (³õÈëÎÄ̳)


[½»Á÷] ¡¾2016-3-20¡¿¡¾´óÁ¬¡¿2016µÚ°Ë½ì¹ú¼Ê¿¹Ìå´ó»á

»áÒé³ÇÊÐ:
´óÁ¬
ÊÇ·ñEi/ISTPÊÕ¼:
δ±»ÊÕ¼
½Ø¸åÈÕÆÚ:
2016Äê3ÔÂ20ÈÕ

2016µÚ°Ë½ì¹ú¼Ê¿¹Ìå´ó»á
ʱ¼ä£º2016Äê4ÔÂ25-28ÈÕ
µØµã£ºÖйú ´óÁ¬
Ö÷Ì⣺¼ÓËÙÏÂÒ»´ú¿¹ÌåµÄÑз¢
»áÒéÍøÕ¾£ºhttps://www.bitcongress.com/ica2016/default.asp

       ¹ú¼Ê¿¹Ìå´ó»áÒѾ­³É¹¦¾Ù°ì¹ýÆß½ì£¬ÒѳÉΪȫÇò¿¹ÌåÑо¿ÁìÓò×îרҵµÄ»áÒéÖ®Ò»¡£´ó»áÖÂÁ¦ÓÚΪȫÇòµÄ¿ÆÑ§¹¤×÷Õß¡¢Ñо¿»ú¹¹ºÍÏà¹ØÆóÒµ´î½¨Ò»¸ö×ÔÓɽ»Á÷µÄƽ̨£¬¼ÓÇ¿Õþ¸®×éÖ¯¡¢´óѧ¡¢Ñо¿»ú¹¹ºÍÆóÒµÖ®¼äµÄ¹µÍ¨ÓëЭ×÷£¬½øÒ»²½ÍƽøÖйúºÍÈ«ÊÀ½çÔÚ¿¹ÌåÑо¿ºÍÖÎÁÆÁìÓòµÄнøÕ¹¡£
       ±¾½ì´ó»á½»Á÷ÄÚÈݰüÀ¨¿¹ÌåÑо¿Ð¼¼ÊõÐÂÇ÷ÊÆ£¬¿¹ÌåÒ©ÎïÑз¢¼°ÖÎÁÆ£¬¿¹ÌåÒ½ÁÆÕï¶Ï£¬¿¹Ì幤³Ì¼°Éú²ú¡¢ÉÌÎñºÏ×÷µÈ20¶à¸öרҵÐÔÂÛ̳£¬Ö¼ÔÚ´«µÝ¿¹ÌåÑо¿ÁìÓò¸÷¸ö·½ÃæµÄ×îÐÂ×ÊѶ£¬Õ¹Ê¾Í»ÆÆÐÔÑо¿³É¹û¡£´ó»á×éί»á½«ÑûÇë3λŵ±´¶û½±´óʦ³öϯ¿ªÄ»Ê½£¬²¢×öÖ÷Ìⱨ¸æ¡£»¹½«ÑûÇë¹ú¼ÊÖøÃûר¼ÒѧÕß¡¢¿¹ÌåÑз¢¹ú¼ÊÖØµãʵÑéÊÒ¡¢´óѧ¡¢Ñо¿ËùµÄÖ÷Òª¸ºÔðÈË¡¢¿¹ÌåÉú²úºÍÏúÊÛÆóÒµµÄ¸ß¹Ü×öרÌⱨ¸æ¡£

Ö÷ÌâÑݽ²ÈË
Dr. Patrick Liu, Vice President, Teva Pharmaceuticals Ltd., USA
Dr. Jose de Chastonay, Chief Marketing Officer, Bachem Holding AG, Switzerland
Dr. Vadim T. Ivanov, Director and Professor, Russian Academy of Sciences, Russia
Dr. Kelly T. McKee, Vice President, Quintiles Inc., USA
Dr. Zhenping Zhu, Executive Vice President, Biologics President & CEO, Kadmon China, USA

Ó¢ÎÄ·Ö×éÂÛ̳£¨Ñݽ²ÓïÑÔΪӢÎÄ£©

Track 1 Global Antibody Market Trend, Business and Partnering
Track 1-1 Promising Future and Challenge, Business and Cooperation in World Antibody Market
Track 1-2 Industry Aspects, Policy, Regulation, IP Issues, Business and Trends in Antibody Market
Track 1-3 IP Issues

Track 2 New Technologies and Trends in Antibody Research
Track 2-1: Novel Research in Immune System, Immunology and Immunogenicity of Antibodies
Track 2-2: Immunoglobulin Diversity, Antibody Characterization Technologies and Structure Biology
Track 2-3: Novel Antibody Library Technologies and Microarray Technologies, Nanotechnology, Biochips, Phage Display Technologies for Antibody Research
Track 2-4: Enabled High Throughput/Content Technologies for Antibody Research - From Antibody Screening, Selection to Optimization Technologies
Track 2-5: Antibody Humanization Technologies
Track 2-6: Exploiting the Immune System and Immunotherapeutic Strategies ¨C from Vaccines to Cell-based and Protein Immunotherapy
Track 2-7: Glycoengineered Antibodies, Agonist and Super-agonist Antibodies
Track 2-8: Monovalent, Multivalent Antibodies, Fragments, Single-domain Antibody, and scFv

Track 3 Advances in Antibody Drug and Therapy
Track 3-1: Challenges and New Opportunities with Antibody and Protein Drugs
Track 3-2: Innovative Antibody drugs in Clinical Trail and Development
Track 3-3: Novel Antibody and Biologic Drug Targets
Track 3-4: Antibody-drug Conjugate (ADC) Discovery and Development
Track 3-5: Bispecific and Multispecific antibody discovery and development
Track 3-6: Next Generation of Cancer Immune therapy and Anti-Cancer Antibody
Track 3-7: Novel Therapeutic Antibodies for Infectious and Inflammatory Diseases
Track 3-8: Novel Therapeutic Antibodies for Allergy, Asthma and Autoimmune Diseases
Track 3-9: Antibodies for Pediatrics Diseases
Track 3-10: Therapeutic Antibodies for Neurological Disease and other Neglected Diseases

Track 4 Antibody Applications in Medical Diagnosis and other Non-Medical Field
Track 4-1: Novel Antibodies in Medical Treatment and Diagnosis
Track 4-2: Biomarker Development - Correlating with Antibody Therapy
Track 4-3: Antibodies for Immunohistochemistry and Immunofluorescence
Track 4-4: Antibody for Western Blot Analyses, ELISA and ELISPOT Techniques
Track 4-5: Antibody Research in Agriculture, Aquaculture, Veterinary and Food Sciences
Track 4-6: The ¡°standardisation¡± of Methods Using Antibodies for the Detection of Diseases and other Issues

Track 5 Antibody Design, Engineering and Production
Track 5-1: Analytical Strategies for Early Phase Protein Engineering and New Antibody Formats
Track 5-2: Advances in Antibody Engineering and Design Strategies
Track 5-3: Cell Line and Model Organisms Development for Antibodies
Track 5-4: Novel Upstream Bioprocess Technologies in Antibody Production
Track 5-5: Optimised Platform for Downstream Processing of Antibodies
Track 5-6: Improved Purification and Modification Methods for Antibody Fragments
Track 5-7: Novel Expressing Platform for Antibody Production
Track 5-8: Biosimilars and Biobetters - Methods and Protocols

Èç¹ûÄúÓÐÑݽ²»ò²Î»áµÄÒâÏò£¬ÇëÏÈÓë»áÎñ×éÁªÏµ¡£

ÁªÏµ·½Ê½
ÁªÏµÈË£ºÕÅŮʿ
µç»°£º0411-84799609-842
ÓÊÏ䣺dannie@bit-ica.com
µØÖ·£º´óÁ¬ÊиßÐÂÔ°Çø»ãÏÍÔ° 1 ºÅ 11 ²ã
Óʱࣺ116025

» ²ÂÄãϲ»¶

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

qwerty200696

ľ³æ (ÖøÃûдÊÖ)


¡ï
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
O(¡É_¡É)Oлл
13Â¥2016-01-22 11:31:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wmwyx

ÖÁ×ðľ³æ (ÎÄ̳¾«Ó¢)


¡ï
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
24Â¥2016-01-22 12:10:01
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
hxlhxl-12Â¥
2016-01-22 11:17   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ºÃ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
ÌìÑÄsx3Â¥
2016-01-22 11:20   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ԭö4¥
2016-01-22 11:22   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
2016-01-22 11:22   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
mike20006Â¥
2016-01-22 11:24   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
2016-01-22 11:25   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
SilenceGoo8Â¥
2016-01-22 11:26   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
a
ZRZR9Â¥
2016-01-22 11:26   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ºÃ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
syhorchid10Â¥
2016-01-22 11:28   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ymz-111Â¥
2016-01-22 11:28   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
2016-01-22 11:29   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ÖÐɽÑò14Â¥
2016-01-22 11:38   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
bixuejian15Â¥
2016-01-22 11:39   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
1
tzynew16Â¥
2016-01-22 11:44   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
billie11317Â¥
2016-01-22 11:46   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
jerry_dlut18Â¥
2016-01-22 11:59   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
2016-01-22 12:00   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
nono200920Â¥
2016-01-22 12:05   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
¡¤
matianvc21Â¥
2016-01-22 12:07   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
yukaiv22Â¥
2016-01-22 12:08   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ö§³Ö
gaomanb23Â¥
2016-01-22 12:08   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
liuzhuit25Â¥
2016-01-22 12:13   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
maoanj26Â¥
2016-01-22 12:13   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
tbs2027Â¥
2016-01-22 12:14   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
zhifang88928Â¥
2016-01-22 12:17   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ŷ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
meifangy29Â¥
2016-01-22 12:19   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
yongxiny30Â¥
2016-01-22 12:20   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
½£Ö®ºá31Â¥
2016-01-22 12:20   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
¾Í ·¢×ÔСľ³æAndroid¿Í»§¶Ë
chenyangl32Â¥
2016-01-22 12:21   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
chaoluib33Â¥
2016-01-22 12:21   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
jiunaj34Â¥
2016-01-22 12:21   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
shenmiaow35Â¥
2016-01-22 12:22   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
tudiank36Â¥
2016-01-22 12:22   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
nieliangl37Â¥
2016-01-22 12:25   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ö§³Ö
2016-01-22 12:25   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ŷ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
2016-01-22 12:26   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
yuhuaw40Â¥
2016-01-22 12:26   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
fengzuoy41Â¥
2016-01-22 12:27   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
liangluoj42Â¥
2016-01-22 12:28   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ºúæÃ1743Â¥
2016-01-22 12:29   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
£¡ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
sunnaiv44Â¥
2016-01-22 12:32   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
fangfenj45Â¥
2016-01-22 12:32   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
fengyingm46Â¥
2016-01-22 12:32   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ö§³Ö
stirith47Â¥
2016-01-22 12:38   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
С³æ199248Â¥
2016-01-22 12:39   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
rongtianv49Â¥
2016-01-22 12:40   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
chenguw50Â¥
2016-01-22 12:41   »Ø¸´  
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ dz×Ï΢À¶ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 285Çóµ÷¼Á +11 ŶßϺôo 2026-04-04 11/550 2026-04-05 17:59 by Öí»á·É
[¿¼ÑÐ] µ÷¼Á +5 ºÃºÃ¶ÁÊé¡£ 2026-04-01 5/250 2026-04-05 17:54 by liucky
[¿¼ÑÐ] 295Çóµ÷¼Á +8 FZAC123 2026-04-03 8/400 2026-04-05 17:46 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 288Çóµ÷¼Á +7 ûÓдð°¸_ 2026-04-05 7/350 2026-04-05 17:01 by yulian1987
[¿¼ÑÐ] 323Çóµ÷¼Á£¨¼ÆËã»úÊÓ¾õºÍ´óÄ£ÐÍÏîÄ¿¾­Àú£© +3 chaoxiicy 2026-03-31 3/150 2026-04-05 10:33 by zhq0425
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉϺ£´óѧÉúÎïѧ346 +3 ÉϺ£´óѧ346µ÷¼Á 2026-04-03 3/150 2026-04-04 20:20 by dongzh2009
[¿¼ÑÐ] 22408Çóµ÷¼Á 354·Ö ¿É¿çרҵ +3 hannnnnnn 2026-04-04 3/150 2026-04-04 14:35 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] 0703Çóµ÷¼Á +6 zizimo 2026-03-31 6/300 2026-04-04 14:16 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 320µ÷¼Á +4 ũҵ¹¤³ÌÓëÐÅÏ¢¼ 2026-04-03 4/200 2026-04-03 21:40 by lbsjt
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +6 ´Þwj 2026-04-02 6/300 2026-04-03 10:19 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 262Çóµ÷¼Á +6 ÀøÖ¾Ò»¶¨·¢ÎÄÕ 2026-04-02 7/350 2026-04-03 09:54 by linyelide
[¿¼ÑÐ] ר˶ 351 086100 Ò²ÊÇ¿¼µÄ²Ä¿Æ»ù ±¾¿ÆÒ²ÊDzÄÁÏ +8 202451007219 2026-04-02 8/400 2026-04-03 09:50 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 312Çóµ÷¼Á +4 ÉÞÔÂÉ« 2026-04-02 5/250 2026-04-03 08:21 by fangshan711
[¿¼ÑÐ] 0805Çóµ÷¼Á +8 ÊÇË®·Ö 2026-03-31 8/400 2026-04-02 10:46 by guanxin1001
[¿¼ÑÐ] Ò»Ö¾Ô¸ÏÃÃÅ´óѧ»¯Ñ§¹¤³Ì£¨×¨Ë¶£©-Êý¶þÓ¢¶þ406·Ö-Çóµ÷¼Á +5 Ïô󻯹¤ 2026-04-01 5/250 2026-04-02 10:03 by jp9609
[¿¼ÑÐ] Çóµ÷¼Á0703 +5 ÖܼÎÒ¢ 2026-03-31 8/400 2026-04-01 20:32 by ltltkkk
[¿¼ÑÐ] 353Çóµ÷¼Á +4 À­¹³²»Ðí±ä 2026-04-01 4/200 2026-04-01 18:10 by ¼Çʱ¾2026
[¿¼ÑÐ] 301Çóµ÷¼Á +8 axibli 2026-04-01 8/400 2026-04-01 09:51 by ÎҵĴ¬Îҵĺ£
[¿¼ÑÐ] 339Çóµ÷¼Á +5 zjjkt 2026-03-31 5/250 2026-04-01 09:18 by JourneyLucky
[¿¼ÑÐ] ±¾2Ò»Ö¾Ô¸C9-333·Ö£¬²ÄÁÏ¿ÆÑ§Ó빤³Ì£¬Çóµ÷¼Á +9 ÉýÉý²»½µ 2026-03-31 9/450 2026-03-31 18:01 by Î޼ʵIJÝÔ­
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û